IP Library Granted Patent US 10,772,991
Granted Patent B2
US 10,772,991 · App. 16/088,967 · Granted Sep 15, 2020

Polyacrylamide hydrogel for use in the prevention and/or treatment of synovitis in a mammal

Inventors: Ieva Ankorina-Stark (Nivå, DK); Lise Hanne Christensen (Frederiksberg, DK)
Assignee: Contura International A/S
A61L27/52A61K31/16A61K31/785A61L27/16A61P19/02C08F220/56C08L33/26A61L2400/06A61L2430/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,772,991
App. No.
16/088,967
Granted
Sep 15, 2020
Kind
B2
Abstract

The present invention relates to a polyacrylamide hydrogel for use in prevention and/or treatment of synovitis or pain associated with synovitis in a mammal by formation of an extra layer to the synovial membrane i.e. a sub-synovial layer and a novel synovial lining layer. Synovitis may occur in association with arthritis, such as osteoarthritis or rheumatoid arthritis, lupus, or gout, and the mammal suffering from synovitis is a preferably a human, a racing animal or a companion animal.

Claims (30)

1. A method of ameliorating synovitis in a mammal comprising:

selecting a mammal to receive a sub-synovial layer or a novel synovial lining layer; and

administering a polyacrylamide hydrogel to an intraarticular cavity of the mammal to generate the sub-synovial layer or novel synovial lining layer comprising said polyacrylamide hydrogel.

2. The method according to claim 1 , wherein the sub-synovial layer or the novel synovial lining layer persists for up to 15 months.

3. The method according to claim 1 , wherein the polyacrylamide hydrogel is administered by injection under sterile conditions.

4. The method according to claim 1 , wherein the polyacrylamide hydrogel is administered by intraarticular injection.

5. The method according to claim 1 , wherein 0.1-20 ml polyacrylamide hydrogel is administered by injection into the intraarticular cavity.

6. The method according to claim 1 , wherein 0.1-20 ml polyacrylamide hydrogel is administered by injection into the intraarticular cavity at least twice.

7. The method according to claim 1 , wherein 0.1-20 ml polyacrylamide hydrogel is administered by injection into the intraarticular cavity at regular intervals.

8. The method according to claim 1 , wherein the mammal is a human, a racing animal or a companion animal.

9. The method of claim 1 , wherein the mammal is a human and the polyacrylamide hydrogel is administered to a joint selected from the group consisting of a knee, a hip, an elbow, a metacarpal-phalangeal and interphalangeal joint in hands or feet, a sesamoid joint and the temporomandibular joint.

10. The method according to claim 1 , wherein the mammal is a horse and the polyacrylamide hydrogel is administered to a fetlock, coffin, pastern, stifle, or knee joint of the hind leg.

11. The method according to claim 1 , wherein the mammal is a dog and the polyacrylamide hydrogel is administered to the elbow of the front leg or the knee or hip joint of the hind leg.

12. The method of claim 1 , wherein the mammal is suffering from arthritis, osteoarthritis, rheumatoid arthritis, lupus, or gout.

13. The method according to claim 12 , wherein the mammal is suffering from osteoarthritis or rheumatoid arthritis.

14. A method of ameliorating synovitis in a mammal comprising:

administering a polyacrylamide hydrogel to an intraarticular cavity of a mammal to generate a sub-synovial layer or a novel synovial lining layer comprising said polyacrylamide hydrogel; and

evaluating said mammal for the formation of the sub-synovial layer or the novel synovial lining layer.

15. The method according to claim 14 , wherein the sub-synovial layer or the novel synovial lining layer persists for up to 15 months.

16. The method according to claim 14 , wherein the polyacrylamide hydrogel is administered by injection under sterile conditions.

17. The method according to claim 14 , wherein the polyacrylamide hydrogel is administered by intraarticular injection.

18. The method according to claim 14 , wherein 0.1-20 ml polyacrylamide hydrogel is administered by injection into the intraarticular cavity.

19. The method according to claim 14 , wherein 0.1-20 ml polyacrylamide hydrogel is administered by injection into the intraarticular cavity at least twice.

20. The method according to claim 14 , wherein 0.1-20 ml polyacrylamide hydrogel is administered by injection into the intraarticular cavity at regular intervals.

21. The method according to claim 14 , wherein the mammal is a human, a racing animal or a companion animal.

22. The method of claim 14 , wherein the mammal is a human and the polyacrylamide hydrogel is administered to a joint selected from the group consisting of a knee, a hip, an elbow, a metacarpal-phalangeal and interphalangeal joint in hands or feet, a sesamoid joint and the temporomandibular joint.

23. The method according to claim 14 , wherein the mammal is a horse and the polyacrylamide hydrogel is administered to a fetlock, coffin, pastern, stifle, or knee joint of the hind leg.

24. The method according to claim 14 , wherein the mammal is a dog and the polyacrylamide hydrogel is administered to the elbow of the front leg or the knee or hip joint of the hind leg.

25. The method of claim 14 , wherein the mammal is suffering from arthritis, osteoarthritis, rheumatoid arthritis, lupus, or gout.

26. The method according to claim 25 , wherein the mammal is suffering from osteoarthritis or rheumatoid arthritis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2018
From: ANKORINA-STARK, IEVA; CHRISTENSEN, LISE HANNE
To: CONTURA INTERNATIONAL A/S
Reel/Frame 047019/0273 →
Priority Claims (1)
EP 16163450 · Mar 31, 2016 · regional
Continuity (1)
Related Publication 20190307925A1 · Oct 10, 2019